AN ENLIGHTENING session, entitled ‘Emerging therapeutic frontiers in cardiology: what does the future hold?’, delivered at ...

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with ...

-- Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin -- Sapablursen was generally safe and well ...

Cancer is often perceived as a fate, but what if it could be avoided even before it manifests? Scientists have just taken a ...

BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...

Faiz Ahmad Taiyeb, Chief Adviser’s Special Assistant for Posts Telecommunications and ICT, said that Bangladesh is working on a policy to regulate the use of Artificial Intelligence (AI) in government ...

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S.

Bladder carcinoma usually arises from the urothelium and is strongly linked to smoking and chemical exposure. It often ...

Data from Phase 2 Trials Underscore Cardioprotective Potential GRAND RAPIDS, Mich., Dec. 9, 2025 /PRNewswire/ -- Cirius Therapeutics, ...

Michael Pearson, who spent 15 years in prison for a crime he didn’t commit, reflects on life and discusses plans to file a ...

Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...